Free Thyroxine, Anti-Thyroid Stimulating Hormone Receptor Antibody Titers, and Absence of Goiter Were Associated with Responsiveness to Methimazole in Patients with New Onset Graves' Disease
Hoon Sung Choi (Choi HS), Won Sang Yoo (Yoo WS)
Endocrinol Metab. 2017;32(2):281-287.   Published online 2017 Jun 23     DOI: https://doi.org/10.3803/EnM.2017.32.2.281
Citations to this article as recorded by Crossref logo
Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves’ disease and predictors of responsiveness to methimazole
KunY Liu, Yu Fu, TianT Li, SunQ Liu, DouD Chen, ChengC Zhao, Yun Shi, Yun Cai, Tao Yang, XuQ Zheng
Clinical Biochemistry.2021; 97: 34.     CrossRef
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
Endocrinology and Metabolism.2019; 34(3): 268.     CrossRef
When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued?
Suyeon Park, Eyun Song, Hye-Seon Oh, Mijin Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Doo Man Kim, Won Bae Kim
Endocrine.2019; 65(2): 348.     CrossRef